Digital sleep phenotype and wrist actigraphy in individuals at clinical high risk for psychosis and people with schizophrenia spectrum disorders: a systematic review and meta-analysis.

IF 4.9 0 PSYCHIATRY BMJ mental health Pub Date : 2025-02-10 DOI:10.1136/bmjment-2024-301337
Rosario Aronica, Edoardo Giuseppe Ostinelli, Charlotte Austin, Dominic Oliver, Philip McGuire, Paolo Brambilla, John Torous, Andrea Cipriani
{"title":"Digital sleep phenotype and wrist actigraphy in individuals at clinical high risk for psychosis and people with schizophrenia spectrum disorders: a systematic review and meta-analysis.","authors":"Rosario Aronica, Edoardo Giuseppe Ostinelli, Charlotte Austin, Dominic Oliver, Philip McGuire, Paolo Brambilla, John Torous, Andrea Cipriani","doi":"10.1136/bmjment-2024-301337","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To identify sleep abnormalities in individuals at clinical high risk for psychosis (CHR-P) or with schizophrenia spectrum disorders (SSDs) compared with healthy controls (HCs) using wrist actigraphy, and to assess potential differences in the direction of effect with self-reported assessments of sleep.</p><p><strong>Methods: </strong>We conducted a systematic review of observational studies, with the search last updated on 29 April 2024. Primary outcome was total sleep time (TST), with secondary outcomes including time in bed (TIB), sleep latency, sleep efficiency, wake after sleep onset, nighttime awakenings and self-reported sleep quality. Random-effects pairwise meta-analyses were used to summarise the effects of each outcome.</p><p><strong>Results: </strong>Nineteen studies were included, with 18 contributing to the meta-analyses (202 CHR-P, 584 SSD, 582 HC). TST results were inconclusive for CHR-P (MD -4.88 min (95% CI -20.57 to 10.81)), while SSD participants showed an increase in TST compared with HC (MD 106.13 min (86.02 to 124.24)). Factors such as antipsychotic medications (pseudo-R²=88.14%), age (38.89%) and gender (26.29%) partially explained the heterogeneity between subgroups. Additionally, CHR-P individuals exhibited reduced sleep efficiency (MD -2.04% (-3.55 to 0.53)), whereas SSD participants had increased TIB (MD 121.58 min (88.16 to 155.00)) and sleep latency (MD 13.05 min (2.11 to 24.00)). The risk-of-bias assessment ranged from <i>some concerns</i> to <i>high risk</i>.</p><p><strong>Conclusions: </strong>Our analyses identified sleep abnormalities in CHR-P and SSD compared with placebo. However, observed heterogeneity and potential biases across studies may limit the interpretability of findings. These limitations underscore the need for standardised guidelines and more precise participant stratification.</p>","PeriodicalId":72434,"journal":{"name":"BMJ mental health","volume":"28 1","pages":""},"PeriodicalIF":4.9000,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11815447/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMJ mental health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/bmjment-2024-301337","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"0","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To identify sleep abnormalities in individuals at clinical high risk for psychosis (CHR-P) or with schizophrenia spectrum disorders (SSDs) compared with healthy controls (HCs) using wrist actigraphy, and to assess potential differences in the direction of effect with self-reported assessments of sleep.

Methods: We conducted a systematic review of observational studies, with the search last updated on 29 April 2024. Primary outcome was total sleep time (TST), with secondary outcomes including time in bed (TIB), sleep latency, sleep efficiency, wake after sleep onset, nighttime awakenings and self-reported sleep quality. Random-effects pairwise meta-analyses were used to summarise the effects of each outcome.

Results: Nineteen studies were included, with 18 contributing to the meta-analyses (202 CHR-P, 584 SSD, 582 HC). TST results were inconclusive for CHR-P (MD -4.88 min (95% CI -20.57 to 10.81)), while SSD participants showed an increase in TST compared with HC (MD 106.13 min (86.02 to 124.24)). Factors such as antipsychotic medications (pseudo-R²=88.14%), age (38.89%) and gender (26.29%) partially explained the heterogeneity between subgroups. Additionally, CHR-P individuals exhibited reduced sleep efficiency (MD -2.04% (-3.55 to 0.53)), whereas SSD participants had increased TIB (MD 121.58 min (88.16 to 155.00)) and sleep latency (MD 13.05 min (2.11 to 24.00)). The risk-of-bias assessment ranged from some concerns to high risk.

Conclusions: Our analyses identified sleep abnormalities in CHR-P and SSD compared with placebo. However, observed heterogeneity and potential biases across studies may limit the interpretability of findings. These limitations underscore the need for standardised guidelines and more precise participant stratification.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
精神病和精神分裂症谱系障碍患者临床高风险个体的数字睡眠表型和手腕活动图:系统回顾和荟萃分析
目的:利用腕动仪识别临床精神病(chrp)或精神分裂症谱系障碍(ssd)高危人群与健康对照组(hc)的睡眠异常,并评估自我报告睡眠评估在影响方向上的潜在差异。方法:我们对观察性研究进行了系统综述,最后一次更新于2024年4月29日。主要结局为总睡眠时间(TST),次要结局包括床上时间(TIB)、睡眠潜伏期、睡眠效率、睡眠开始后醒来、夜间醒来和自我报告的睡眠质量。随机效应两两荟萃分析用于总结每个结果的影响。结果:19项研究被纳入,其中18项对meta分析有贡献(202项chrp, 584项SSD, 582项HC)。CHR-P的TST结果不确定(MD -4.88 min (95% CI -20.57至10.81)),而SSD参与者的TST与HC相比增加(MD 106.13 min(86.02至124.24))。抗精神病药物(伪r²=88.14%)、年龄(38.89%)和性别(26.29%)等因素部分解释了亚组间的异质性。此外,chrp个体表现出睡眠效率降低(MD -2.04% (MD -3.55至0.53)),而SSD参与者的TIB (MD - 121.58分钟(MD - 88.16至155.00))和睡眠潜伏期(MD - 13.05分钟(MD - 2.11至24.00))增加。偏倚风险评估范围从一些担忧到高风险。结论:与安慰剂相比,我们的分析确定了chrp和SSD患者的睡眠异常。然而,观察到的异质性和潜在的偏倚可能会限制研究结果的可解释性。这些限制强调了标准化指南和更精确的参与者分层的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.80
自引率
0.00%
发文量
0
期刊最新文献
Identifying postpartum depression subtypes using natural language processing and clinical notes. Discontinuation and reinitiation of pharmacological treatment for ADHD among individuals with ADHD and substance use disorder. International Depression Questionnaire and International Anxiety Questionnaire: validation of brief ICD-11 measures for depression and generalised anxiety disorder. Reduced risk of cause-specific hospitalisations and all-cause hospitalisation/mortality during treatment with attention-deficit/hyperactivity disorder medications in the course of bipolar disorder: a Swedish registry-based within-subject cohort study. Levels of evidence supporting American, European and international guidelines in psychiatry, 2014-2024: a systematic review with quantitative synthesis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1